Disclaimer
The information provided in this article is for general informational purposes only. While we endeavour to provide accurate and up-to-date information, there may be instances where information is outdated or incorrect. The contents of this article should not be taken as legal advice nor should it be relied upon in making any business, legal or other decisions. We encourage readers to consult with a qualified legal or professional advisor to obtain proper advice based on your unique circumstances. We disclaim any liability for any loss or damage arising out of or in any manner connected with the use of or reliance on the information provided in this article. Note that cannabis regulations in Thailand are evolving rapidly; always consult the Department of Thai Traditional and Alternative Medicine (DTAM) within the Ministry of Public Health and the Thai Food and Drug Administration (Thai FDA) for the latest updates.
ARE YOU READY TO EXPORT INTERNATIONALLY? DOWNLOAD FREE CANNABIS LICENSE GUIDE CHECKLIST FOR THAILAND
Yes, cannabis is legal in Thailand, but only for medical and health purposes. Recreational use is illegal as of 2026, and the rules tightened significantly after so many years of ambiguity.
Thailand’s cannabis space offers a very interesting history. As of 2022, the country became the first in Southeast Asia to decriminalize cannabis, removing it from the narcotics list and unleashing a wave of entrepreneurship. Dispensaries sprouted on every corner in Bangkok, Chiang Mai, and Phuket. Tourists flew in specifically to sample Thai-grown strains and the industry boomed. For over 2 years, Thailand looked like it was embracing a full recreational model by default until late 2024 when public concern over unchecked recreational use, youth access, and regulatory chaos mounted. The turning point came on April 30, 2026, when the Thai government issued Ministerial Regulation No. 2 (B.E. 2569), reclassifying cannabis as a controlled herb under the Herbal Product Act. This single regulation reversed the de facto recreational availability that had defined the post-2022 era. Where over twelve thousand dispensaries once operated with minimal restrictions and no medical prescription was required for purchase, the new framework now demands a PT 33 prescription for all cannabis products.
The effects of this reversal have been sweeping. Thousands of dispensaries that built their business models on the assumption of open access have shuttered or pivoted overnight. Entrepreneurs who invested heavily during the boom now face a compliance landscape that demands medical credentials, qualified on-site personnel, and premises that meet strict FDA standards. The cost of entry has risen, the rules have multiplied, and the margin for error has narrowed to nearly zero. Yet, there’s a big opportunity for those who understand the system. Thailand still runs the region's most advanced medical cannabis program, and licensed operators continue to serve a growing patient base with legitimate needs. That is precisely why we created this guide. Navigating the Thailand cannabis licensing ecosystem in 2026 requires more than enthusiasm; it demands accurate, up-to-date information and practical guidance from people who work inside the system daily. To ensure this guide reflects ground-level reality, we spoke directly with industry experts actively involved in the market, including Sarun Sereethoranakul, Co-Founder and COO of Iridescent Med, who shared firsthand insights on what it actually takes to operate compliantly in Thailand's post-2026 framework.
Thailand’s relationship with cannabis is far older and more complex than the modern legalization headlines suggest. Long before dispensaries appeared in Bangkok or tourists began searching for “weed in Thailand,” cannabis was deeply embedded in Thai medicine, cuisine, agriculture, and rural culture.
Today, Thailand stands at the center of Asia’s cannabis conversation. The country became the first nation in Southeast Asia to legalize medical cannabis in 2018 and later decriminalized cannabis in 2022, triggering a massive expansion of the Thai cannabis industry. However, by 2025 and 2026, the government began tightening regulations again, shifting the market back toward a more medically focused framework.
While cannabis grows wild in Central Asia and the Indian Himalayas, its origin in Thailand is unclear. Some experts believe it was introduced into the region by Indian merchants, who also brought along the term ganja, which is derivable from the Sanskrit word gunja and is reflected in the vernacular name in the following southeast Asian countries: Thailand (kancha), Cambodia (Kanhcha), Laos (Kan xa), and Vietnam (can xa).
For centuries, cannabis existed in Thailand not as a criminal substance, but as a practical agricultural and medicinal plant integrated into daily life. Before prohibition laws emerged in the twentieth century, cannabis was commonly used across Thailand in multiple forms including food, fiber and textiles.
One of the most well-known traditional uses of cannabis in Thailand was in cooking. Cannabis leaves and roots were sometimes added to soups and broths, particularly among laborers and farming communities. The plant was believed to help reduce fatigue, stimulate appetite, and promote relaxation after long hours of physical work. Thailand also maintained a long history of hemp cultivation for textile production and rope-making. Hemp fibers were widely used in local industries before global anti-cannabis policies reshaped public attitudes toward the plant. In early Muay Thai history, fighters reportedly used hemp-based hand wraps during matches before Western-style boxing gloves became standardized in the 1920s.
One of the most historically important roles of cannabis in Thailand was its use in traditional medicine. Long before modern legalization debates, cannabis was widely recognized in Thai healing practices as a medicinal herb used to restore balance and improve overall wellness.
The use of cannabis in Thai medicine dates back to the Ayutthaya Kingdom during the reign of King Narai the Great between 1656 and 1688. This period played a major role in preserving Thai medical knowledge through royal medical texts and herbal records. Among the most important of these texts is the Kampee Thart Phra Narai, regarded as one of the earliest compilations of traditional Thai medicinal formulas. The manuscript documented the use of cannabis in remedies designed to address nausea, digestive discomfort, fatigue, pain, appetite loss, and sleep disturbances.
In traditional Thai medicine, cannabis was rarely used alone. Instead, healers combined cannabis leaves, roots, and stems with herbs such as ginger, cloves, cinnamon, black pepper, and bay leaves to create balanced herbal remedies. One notable formula, known as Akkhineewakana, blended cannabis with warming herbs to relieve nausea and gastrointestinal discomfort. These formulations reflected the holistic philosophy of Thai medicine, where multiple herbs worked together to improve therapeutic effects while minimizing unwanted reactions.
Although cannabis was criminalized in Thailand during the twentieth century, knowledge of these remedies continued to survive through traditional practitioners and preserved medical manuscripts. When Thailand legalized medical cannabis in 2018, this historical connection became central to the country’s cannabis reform movement. In 2019, the Ministry of Public Health approved several traditional cannabis formulas for regulated medical use, while the Department of Thai Traditional and Alternative Medicine expanded research into historical remedies. By 2021, official publications documented more than 160 traditional Thai cannabis formulas, reinforcing cannabis’ longstanding role in Thailand’s medicinal heritage.
Thailand’s cannabis policies began shifting during the early twentieth century as international narcotics treaties and global anti-drug campaigns started influencing governments around the world. Prior to this period, cannabis had long existed within Thai society as a medicinal herb, culinary ingredient, and agricultural crop with little formal legal restriction. However, growing international concern surrounding narcotics gradually transformed how cannabis was viewed by policymakers.
A major turning point came on January 23, 1912, when Siam, as Thailand was then known, became one of the signatories to the International Opium Convention signed at The Hague. The agreement primarily focused on controlling opium and cocaine trafficking, but it also marked the beginning of Siam’s participation in international narcotics regulation. Over the following years, global drug control efforts expanded beyond opium, and cannabis increasingly came under international scrutiny.
On February 19, 1925, the Second International Opium Convention in Geneva introduced stronger controls over “Indian hemp,” a term widely used at the time to describe cannabis. As international pressure mounted, Siam gradually aligned its domestic policies with emerging global narcotics standards.
In 1922, Thailand enacted the Narcotics Act B.E. 2465, one of the country’s earliest modern drug laws. While the legislation focused broadly on narcotic substances, it established the legal framework that would later support stricter cannabis regulation.
Thailand’s first law specifically targeting cannabis arrived on August 7, 1934, with the enactment of the Cannabis Act B.E. 2477. The law formally criminalized the cultivation, possession, importation, exportation, sale, and distribution of cannabis throughout the Kingdom. It also prohibited cannabis paraphernalia, including traditional smoking devices such as bongs.
Despite its restrictive approach, the 1934 Cannabis Act still permitted limited exemptions for medical research and scientific use, reflecting cannabis’ longstanding role in Thai traditional medicine. Nevertheless, the legislation marked a historic shift away from centuries of cultural acceptance toward a prohibition-based system influenced heavily by international anti-drug policy. By the mid-twentieth century, cannabis had increasingly become associated with narcotics enforcement rather than traditional healing, laying the foundation for the far stricter drug laws Thailand would later adopt under the Narcotics Act of 1979.
Thailand’s cannabis culture gained international attention during the Vietnam War era, but this development did not happen in isolation. It was directly shaped by the earlier legal foundations established in the 1930s, particularly the Cannabis Act of 1934, which had already begun shifting cannabis away from traditional acceptance toward formal prohibition. By the time global military and geopolitical pressures intensified in the 1960s, cannabis in Thailand existed in a dual reality: culturally familiar at the local level, but increasingly illegal under national and international law.
Following the enactment of the Cannabis Act B.E. 2477 in 1934, cannabis cultivation, possession, and distribution were criminalized across Thailand. However, enforcement remained inconsistent in rural areas for several decades, especially where cannabis had long been used in traditional medicine and agriculture. This regulatory gap allowed cultivation practices to continue in certain regions, even as official policy moved toward stricter control.
By the 1960s, this tension between law and practice became more visible. During the Vietnam War (approximately 1965 to 1975), the United States significantly expanded its military presence in Thailand, establishing multiple bases across the country. At the height of the conflict, Thailand became a major logistical and recreational hub for U.S. forces stationed in Southeast Asia.
It was during this period that high-quality Thai cannabis strains gained international exposure. American soldiers stationed in Thailand or passing through on leave encountered locally grown cannabis known for its potency, smooth smoke, and distinct tropical profile. Demand quickly increased, particularly among military personnel seeking relaxation during downtime.
This period gave rise to the legendary “Thai Stick,” a uniquely prepared form of cannabis flower tied around bamboo sticks using hemp fibers and carefully cured for potency and preservation. Thai Stick was not only a local product but a highly refined export form that reflected Thailand’s agricultural expertise and native cannabis genetics.
By the early to mid-1970s, Thai Stick had achieved global recognition, especially in the United States, where it became one of the most iconic imported cannabis products of the era. Its reputation helped cement Thailand’s position in the global cannabis narrative, even as domestic laws remained strictly prohibitive under the post-1934 legal framework.
By the 1970s and 1980s, Thailand’s cannabis landscape reflected a clear contradiction shaped by earlier legislation: while the Cannabis Act of 1934 had formally criminalized the plant, enforcement pressures and global demand contributed to Thailand becoming a significant hub in regional cannabis trafficking networks. International agencies increasingly identified the country as a major source of illicit cannabis production during this time.
Following the international rise of Thai cannabis during the Vietnam War era and the emergence of Thai Stick in global illicit markets, Thailand’s cannabis policy entered a phase of stricter enforcement and deeper alignment with international narcotics control frameworks. What had once been a locally tolerated plant with traditional medicinal roots was now increasingly treated as a controlled substance within a global prohibition system.
By the late twentieth century, Thailand had fully integrated into international drug control architecture. Its participation in the Single Convention on Narcotic Drugs of 1961 and the Convention on Psychotropic Substances of 1971 reinforced a global shift toward uniform narcotics regulation. These agreements influenced domestic policy direction and strengthened Thailand’s commitment to criminal enforcement of controlled substances, including cannabis.
This evolving international framework culminated in the Narcotics Act B.E. 2522 (1979), which consolidated Thailand’s drug laws into a modern centralized system. Under this legislation, cannabis and hemp were classified as Category 5 narcotics, placing them under strict prohibition. The law effectively criminalized cultivation, possession, distribution, import, and export, while allowing only tightly controlled exceptions for scientific and medical research under state authorization.
For decades following the 1979 Act, Thailand maintained a strict enforcement approach, particularly throughout the 1980s, 1990s, and early 2000s. Cannabis remained widely prohibited under national law, even as informal and traditional uses persisted in rural and medicinal contexts.
A significant shift began to emerge in the late 2010s as global attitudes toward cannabis started changing. In 2018, the Thai government began cautiously relaxing its stance on cannabis through the Ministry of Public Health regulation titled “Re: Licensing and Approval for the Production, Distribution or Possession of Narcotics Category V Hemp,” which came into effect on 5 January 2018. This regulation allowed hemp cultivation and possession for medicinal and industrial purposes under strict licensing, particularly through state-approved entities. Later that same year, Thailand made a historic legal breakthrough. On 19 February 2019, the Parliament passed the Narcotics Act (No. 7) B.E. 2562, making Thailand the first country in Southeast Asia to legalize cannabis for medical use and research. While this amendment introduced a legal licensing system for cannabis activities, both cannabis and hemp technically remained classified as Category 5 narcotics. This momentum continued into 2019 with amendments to the Narcotics Act, which formally permitted cannabis use for medical treatment and research under strict regulatory supervision. Although cannabis remained classified as a narcotic, the legal structure now allowed licensed cultivation, production, and controlled medical application.
Political support for reform continued to grow, particularly under the pro-cannabis Bhumjaithai Party, whose leadership held the Ministry of Public Health portfolio. Under this influence, further regulatory easing followed in December 2020 when the Ministry of Public Health issued the announcement “Re: Specification of Type 5 Narcotics B.E. 2563 (2020).” This measure removed certain parts of the cannabis plant, along with CBD extracts containing no more than 0.2 percent THC, from the Category 5 narcotics list, significantly expanding legal space for regulated products.
The most decisive step in this transition came on 9 February 2022, when the Ministry of Public Health announced the removal of cannabis and hemp from the Category 5 narcotics list. This change came into effect on 9 June 2022. Under the new classification, only cannabis and hemp “extracts” remained regulated as narcotics, except for those containing not more than 0.2 percent THC by weight, as well as hemp seed oil derived from domestically cultivated hemp.
Cannabis and hemp’s removal from Thailand’s Category 5 narcotics list on 9 June 2022 marked one of the most significant policy shifts in the country’s modern history. However, rather than creating a fully structured recreational cannabis market, the reform opened a regulatory grey area that rapidly transformed Thailand into one of the most dynamic and uncertain cannabis markets in the world.
In the months immediately following decriminalization in mid-2022, Thailand experienced what many described as a “green rush.” Cannabis businesses expanded at an unprecedented pace across major urban and tourist destinations such as Bangkok, Chiang Mai, Phuket, and Pattaya. Thousands of dispensaries, wellness shops, and cultivation operations emerged within a short period, driven by strong domestic demand and international tourism interest.
This rapid expansion was made possible by the absence of a single comprehensive cannabis control law at the time of decriminalization. Instead, cannabis regulation was managed through a combination of public health announcements, ministerial regulations, and licensing frameworks, which created flexibility but also significant legal uncertainty. One of the most notable ambiguities was the lack of a clearly defined legal framework distinguishing recreational use from medical or wellness-based consumption.
By late 2022 and into 2023, this uncertainty began to attract increased government attention. Concerns emerged around unregulated sales, inconsistent licensing practices, public consumption, and access among minors. Tourism-driven cannabis consumption in some areas further amplified regulatory scrutiny, prompting policymakers to reassess the speed and scope of liberalization.
As a result, Thailand gradually shifted from rapid liberalization toward a more controlled and medical-focused regulatory approach. Authorities began emphasizing that cannabis should primarily be treated as a regulated herbal medicine rather than a recreational consumer product. Licensing requirements for cultivation, distribution, and retail operations became increasingly structured, with greater emphasis placed on compliance, documentation, and permitted use cases.
Between 2023 and 2024, additional regulatory proposals and ministerial guidelines were introduced to tighten oversight of the industry. These measures focused on defining clearer operational boundaries for dispensaries, strengthening inspection systems, and limiting non-medical promotional activities. In parallel, discussions intensified around introducing a comprehensive Cannabis Control Act to replace the fragmented regulatory system that had emerged after 2022.
By 2025 and into 2026, Thailand's cannabis policy direction had clearly shifted toward stricter governance. According to Sarun Sereethoranakul of Iridescent Med, the impact on the ground was severe for some but beneficial for others: "The impact has been very significant, especially for dispensaries and businesses that were built around recreational or tourist walk-in sales. The 2025 policy shift has helped separate serious medical operators from recreational-focused businesses."
Cannabis in Thailand is governed by a layered legal framework that has shifted dramatically since 2022. While removing the plant from the Narcotics schedule in 2022 ended decades of prohibition it did not create a comprehensive recreational framework. Instead, cannabis flower was reclassified as a controlled herb under the Protection and Promotion of Thai Traditional Medicine Knowledge Act B.E. 2542 (1999) on June 26, 2025, placing it under the jurisdiction of the Department of Thai Traditional and Alternative Medicine (DTAM) within the Ministry of Public Health.
The definitive regulatory tightening came on April 30, 2026, when the Royal Gazette published Ministerial Regulation No. 2 B.E. 2569 on the Permission for Study, Research, or Export of Controlled Herbs, or Sale, or Processing of Controlled Herbs for Commercial Purposes. Signed by Minister of Public Health Patthana Promphat on April 29, 2026, and issued under Section 4 paragraph one, Section 46 paragraph two, and Section 49 paragraph two of the Protection and Promotion of Thai Traditional Medicine Knowledge Act B.E. 2542, this regulation imposes strict cannabis-flower-specific licensing criteria on top of the existing 2559 (2016) Ministerial Regulation framework. The regulation took effect on May 1, 2026, and applies to all new applications, pending applications, and renewals for licenses to export, sell, or process cannabis flower for commercial purposes.
Under this framework, cannabis extracts containing more than 0.2% THC by weight remain classified as Category 5 narcotics under the Narcotics Code. A separate Ministerial Regulation on Permission to Produce, Import, Export, Sell or Possess Category 5 Narcotics, Specifically Cannabis or Hemp Plant Extracts, B.E. 2569 (2026) was published in the Royal Gazette on March 26, 2026, and took effect on April 26, 2026, replacing the previous 2021 regulation and limiting extract permissions to four purposes: official narcotics suppression, medical use, analysis/education/scientific research, and industrial use.
Medical cannabis has been legally recognized in Thailand since 2018, when the country became the first in Asia to permit regulated medical use. This reform marked the beginning of Thailand’s transition from strict prohibition toward a structured medical cannabis system rooted in public health and traditional medicine governance.
The current legal framework is governed under the Ministry of Public Health Notification on Controlled Herbs (cannabis), issued under Sections 44 and 45 of the Protection and Promotion of Thai Traditional Medicine Knowledge Act B.E. 2542 (1999). This regulation formally defines cannabis as a controlled herb for medical use under state supervision. As stated in the official regulatory framework, cannabis may be used “for the treatment of patients or for medical and research purposes under licensed control,” reinforcing its restricted but lawful medical status.
Under this system, cannabis flower can only be dispensed to patients holding a valid PT 33 prescription issued by authorized practitioners, including licensed physicians, dentists, or certified traditional Thai medicine doctors. Each prescription is limited to a maximum of 30 days’ supply and must clearly state the diagnosis and approved quantity, ensuring a traceable chain of medical accountability from prescription to dispensing.
Licensed physicians are permitted to prescribe medical cannabis for a defined list of approximately 15 approved conditions, including chronic pain, spasms, cramps, joint pain, muscle stiffness, cancer, nausea and vomiting, Parkinson’s disease, seizures, asthma, insomnia, loss of appetite, general anxiety, Alzheimer’s disease and depression. In addition to diagnostic limits, Thailand enforces strict dosage controls, typically capped at around 30 grams of cannabis flower per patient per month unless otherwise medically justified.
A further regulatory tightening came with Ministerial Regulation No. 2 B.E. 2569 (2026), which reinforces Thailand’s shift toward a strictly medical and institution-based cannabis system. The regulation requires that any entity handling cannabis flower must operate under a recognized health-sector license. This includes hospital operating licenses under the Sanatorium Act, herbal product licenses under the Herbal Products Act B.E. 2562, pharmaceutical licenses under the Drug Act, or certified traditional medicine practitioner registration.
As emphasized in the regulation’s framework, cannabis flower activities are limited to entities engaged in “medical, pharmaceutical, or traditional health service operations,” effectively eliminating standalone recreational retail models. As a result, Thailand’s medical cannabis system functions as a controlled prescription-based framework embedded within the national healthcare system, where access is legal but tightly regulated through professional oversight, licensing, and medical necessity.
Sarun Sereethoranakul, Co-Founder and COO of Iridescent Med, emphasizes that this medical framing is not merely regulatory language but operational reality: "Many outsiders still think Thailand is a simple cannabis retail market, but the latest direction is clearly medical. From our understanding, dispensaries now have a transition period to move toward a clinic or medical-service model, with proper practitioners and medical records. For producers like Iridescent Med, the mindset also has to change. We are not just producing cannabis flower; we are producing medicine. That means we need Thai GACP certification, proper batch records, traceability, and long-term data collection. We can supply only licensed dispensaries or clinics that operate under the medical framework. The government will also continue to stop black-market products and non-compliant operators. This is why proper licensing, source verification, and traceability are becoming more important. In this market, compliance is not paperwork after production — compliance is part of the product."
Recreational cannabis is illegal in Thailand as of 2026. The June 25, 2025 reclassification of cannabis flower as a controlled herb under the Protection and Promotion of Thai Traditional Medicine Knowledge Act B.E. 2542, combined with the April 30, 2026 Ministerial Regulation No. 2 B.E. 2569, eliminated the gray area that had allowed recreational commerce to flourish between 2022 and 2025.
Under the current framework, penalties for recreational use are severe. Public consumption without a valid prescription carries a fine of up to 25,000 THB (~$700) and imprisonment of up to 3 months. Possession without a valid prescription and purchase without a prescription carry identical penalties. Operating an unlicensed dispensary results in license suspension or permanent closure, fines, and potential criminal charges under the Act's penal provisions.
The Notification of the Ministry of Public Health on Controlled Herbs (Cannabis) issued under Sections 44 and 45 of the Act also prohibits sale to minors and pregnant women, bans advertising of cannabis products, and prohibits consumption on licensed premises. Violations of these notifications can trigger license suspension, and under Article 6 of Ministerial Regulation No. 2 B.E. 2569, any licensee previously suspended for non-compliance with these notifications is barred from renewal.
Public consumption is prohibited nationwide, with enhanced penalties for consumption near schools, temples, and other sensitive locations. Tourists should be particularly aware that police enforcement is especially vigilant in tourist areas, and ignorance of the post-2025 legal changes is not accepted as a defense in Thai courts.
Cultivation of cannabis in Thailand is permitted only under regulated, licensed conditions. The Ministerial Regulation No. 2 B.E. 2569 addresses cultivators through Article 8/1(3)(b), which recognizes a cultivation site supplying licensed buyers under Section 46 of the Protection and Promotion of Thai Traditional Medicine Knowledge Act B.E. 2542 as a qualifying applicant status for commercial licenses.
Cultivators must maintain GACP (Good Agricultural and Collection Practice) certification from the Thai FDA and DTAM, document their supply contracts with downstream licensees, and ensure their cultivation premises meet storage and quality-preservation requirements. The regulation specifically requires that cannabis flower be stored separately, not mixed with other materials, and not in direct contact with the floor, with equipment to maintain the flower in good quality.
For extracts exceeding 0.2% THC, cultivation and processing activities fall under the Narcotics Code as Category 5 narcotics, requiring a separate licensing track entirely. The Ministerial Regulation on Permission to Produce, Import, Export, Sell or Possess Category 5 Narcotics, Specifically Cannabis or Hemp Plant Extracts, B.E. 2569 (2026) requires that applicants seeking permission to produce extracts for medical purposes must be juristic persons that are not foreigners under the Foreign Business Act, government agencies, or the Thai Red Cross Society, and must hold a license to produce modern medicine or herbal products.
Importing cannabis seeds without authorization from the Thai FDA is prohibited under plant quarantine regulations and the cannabis regulatory framework.
Importing or exporting any cannabis product into or out of Thailand is strictly prohibited and constitutes a serious criminal offense, regardless of the laws in the destination or origin country.
For cannabis flower classified as a controlled herb, the Ministerial Regulation No. 2 B.E. 2569 states that exporters must demonstrate that the destination market's import permit exists and that the foreign buyer is authorized to receive cannabis flower under that jurisdiction's rules. This disqualifies any business model that ships to consumers or non-licensed wholesalers in destination markets. Thailand has strategically positioned cannabis flower as a medical input rather than a recreational commodity, and exports are permitted only within a closed, licensed, medically oriented system.
For extracts containing more than 0.2% THC, which remain Category 5 narcotics, the Ministerial Regulation B.E. 2569 (2026) imposes even stricter controls. Applicants seeking permission to import or export such extracts for medical or industrial purposes must be juristic persons that are not foreigners, government agencies, or the Thai Red Cross Society. For each import or export transaction, licensed importers or exporters must obtain specific permission every time they import or export. They cannot rely on a standing general license.
The Thai FDA explicitly prohibits the importation of herbal products containing cannabis or hemp for personal use. Travelers attempting to bring cannabis products through Thai customs in either direction face immediate seizure and criminal prosecution under the Narcotics Act and related customs laws. The penalties are severe and apply regardless of whether the traveler possesses a valid prescription from their home country.
Operating a cannabis-related business in Thailand require a multi-layered fee structure which is primarily regulated by the Ministry of Public Health, the Food and Drug Administration (Thai FDA), and the Department of Thai Traditional and Alternative Medicine (DTAM). Costs vary depending on whether the activity involves medical cannabis, industrial hemp, cultivation, processing, or product registration.
Rather than a single licensing fee, operators must budget for application fees, annual license fees, product registration charges, and ongoing compliance costs across different regulatory bodies.
Medical cannabis licensing in Thailand operates under the Narcotics Act framework and Ministry of Public Health notifications governing controlled herbs. Applicants seeking to cultivate, manufacture, or distribute medical cannabis must apply through authorized channels, often under hospital, pharmaceutical, or traditional medicine licensing structures.
Typical cost components include:
In practice, medical cannabis licensing costs vary significantly depending on operational scale, with institutional applicants such as hospitals or licensed pharmaceutical operators carrying higher compliance and infrastructure requirements than smaller traditional medicine clinics.
According to industry sources, FDA license fees range from THB 5,000 for a dispensary to THB 50,000 for a cultivation license. A separate cannabis sales license obtained through DTAM carries an application fee of 20 Baht and a license fee of 3,000 Baht per 3 calendar years.
These government fees, however, represent only a fraction of the total cost. A realistic startup budget must account for company registration, premises setup, staffing, and compliance infrastructure. Industry estimates place total startup costs between THB 500,000 and THB 3,000,000 depending on license type, location, and scale. Applications filed directly through the FDA in Bangkok typically take 2 to 3 months, while provincial health office routes require 4 to 5 months.
Industrial hemp in Thailand operates under a separate regulatory track from medical cannabis, though the two share some overlapping requirements. Hemp is defined as cannabis containing less than 0.2% THC by dry weight, and its cultivation, processing, and sale require distinct authorizations.
The Draft Bill for Cannabis and Hemp currently under parliamentary review specifies that license fees will be determined by ministerial regulations issued by the Ministry of Public Health, subject to maximum rates outlined in the bill's annex. This includes the following
Fee amounts will vary based on cultivation area, quantities of hemp or extracts handled, or the size of the licensee's business. For hemp-derived CBD products, the regulatory threshold is strict. Extracts containing more than 0.2% THC remain classified as Category 5 narcotics under the Narcotics Code, regardless of whether they originate from hemp or cannabis.
Hemp businesses must also secure GACP certification for cultivation activities, with costs comparable to medical cannabis operations. The certification requires facility inspections, documentation systems, and ongoing compliance maintenance that add substantially to the base license fee.
Any cannabis product intended for sale, whether flower, oil, edible, or topical, must undergo sanitary registration and product approval with the Thai FDA. This process ensures compliance with the Herbal Products Act B.E. 2562, the Drug Act, or the Food Act, depending on product classification.
For food and beverages containing CBD extracts, operators must apply for food registration or permission to use food labels, plus registration of the food production location and food serial number. These registrations are managed by the FDA and require submission of:
Lab testing costs run from THB 3,000 to 10,000 per batch for potency and contamination screening. Products that fail testing must be reformulated or destroyed, creating additional cost risk. For manufacturers producing multiple SKUs, the registration burden multiplies, each distinct product requires separate FDA approval.
Dispensaries and clinics face their own sanitary compliance costs. Premises must pass hygiene, security, and zoning inspections before licensing, and ongoing compliance requires maintenance of climate control, sanitation standards, and waste disposal protocols.
The 2026 regulatory framework under Ministerial Regulation No. 2 B.E. 2569 imposes ongoing compliance obligations that carry real financial weight. Licensees must maintain:
GACP Certification (for cultivators):
Odor and Smoke Elimination Systems:
Under Article 4 of Ministerial Regulation No. 2 B.E. 2569, all cannabis-flower licensees must install "an effective odor and smoke elimination system" at their premises. The regulation does not prescribe specific equipment, but DTAM interprets this to mean activated carbon filtration, sealed extraction systems, negative-pressure design for processing rooms, and documented maintenance logs. Retrofit budgets for older dispensary build-outs should account for THB 100,000 – 300,000 in ventilation and filtration infrastructure.
Trained Staffing Requirements:
Article 8/1(4) of the 2569 regulation requires at least one DTAM-trained staff member on duty at all times during operating hours. Training costs vary, but operators must budget for initial certification plus ongoing education as curricula update.
Monthly Reporting Obligations:
Licensees must file Forms like Phor.Tor.27, 28, and 29 to DTAM covering production quantities, sales records, inventory tracking, and prescription verification. While the forms themselves carry no fee, the administrative burden requires dedicated staff or outsourced compliance support.
Renewal and Re-qualification Costs:
Under Article 5 of Ministerial Regulation No. 2 B.E. 2569, license renewals must be reassessed against all original approval criteria plus the new Article 8/1 requirements. This transforms renewal from an administrative event into a substantive re-qualification, often requiring legal review, premises upgrades, and re-documentation at THB 50,000 – 150,000 per renewal cycle.
Failure to maintain compliance triggers severe financial penalties. Operating without a license carries up to 3 years imprisonment and fines up to THB 300,000. License suspension under the Ministry of Public Health Notifications issued under Sections 44 and 45 of the Protection and Promotion of Thai Traditional Medicine Knowledge Act B.E. 2542 creates an additional penalty: Under Article 6 of the 2569 regulation, any licensee previously suspended for such violations is barred from renewal entirely.
Note: Importing cannabis/herbal products for personal use is prohibited
Note: Prior suspension under Sections 44–45 notifications = barred from renewal (Article 6, 2569 Regulation)
How to Get a Cannabis License in Thailand
Obtaining a cannabis license in Thailand in 2026 requires navigating a multi-step process that demands precision, patience, and thorough preparation. The regulatory framework under Ministerial Regulation No. 2 B.E. 2569 has raised the barrier to entry significantly, and applications that would have sailed through in 2022 now face substantive scrutiny. This section walks through the practical steps from initial planning to operational approval.
Step 1: Determine Your License Type and Qualifying Status
Before filing any paperwork, identify which license category matches your business model. The Protection and Promotion of Thai Traditional Medicine Knowledge Act B.E. 2542 governs controlled herbs, and Ministerial Regulation No. 2 B.E. 2569 applies specifically to cannabis flower licenses for export, sale, or processing. Your options include:
Critically, under Article 8/1(3) of the 2569 regulation, you must hold a qualifying status before applying for a cannabis-flower license. This means securing your hospital license, herbal product license, pharmaceutical license, Category 5 narcotics license, or folk healer certification first, then layering the cannabis-flower license on top. Many entrants find the most efficient path is to first secure a Herbal Products Act sales license or a sanatorium clinic license, then add the cannabis-flower authorization.
Step 2: Secure Compliant Premises
Your premises must satisfy Article 8/1(1) of the 2569 regulation: you must hold ownership or possessory rights, or attach written owner consent if leasing. The premises must also qualify as a medical facility, licensed pharmacy, or registered herbal retailer under the new rules. For dispensaries, this means converting from a freestanding retail shop to a clinic or pharmacy format.
Key premises requirements include:
Step 3: Complete DTAM Staff Training
Under Article 8/1(4), at least one staff member who has completed training from the Department of Thai Traditional and Alternative Medicine must be present throughout operating hours. DTAM publishes its training calendar and curriculum on its official website. Map your staff rosters to opening hours, build a training pipeline to cover turnover, and document completion in employee files for inspection. Multiple locations require trained staff at each branch.
Step 4: Prepare and Submit Application
Applications are filed with the Department of Thai Traditional and Alternative Medicine, Ministry of Public Health under Article 13(1) of the 2559 regulation as amended. The 2569 amendment introduced a new Article 4/1 requiring cannabis-flower-specific application forms that capture the additional Article 8/1 criteria information.
Your submission must include:
Applications filed directly through DTAM in Bangkok typically take 2 to 3 months; provincial health office routes require 4 to 5 months. Pending applications filed before April 30, 2026 are deemed applications under the amended regulation, and the licensing authority may direct applicants to bring files into compliance with the new criteria.
Step 5: Pass Inspection and Address Deficiencies
DTAM and provincial public health officers conduct premises inspections focusing on:
Expect odor and smoke compliance to be a primary inspection focus in 2026 and 2027. If deficiencies are identified, the licensing authority may issue a corrective notice requiring specific remedial action before approval.
Step 6: Receive License and Maintain Compliance
Upon approval, your license is valid for the period specified, typically 3 calendar years for sale licenses with a fee of THB 3,000. Existing licenses issued under the 2559 regulation remain valid until their natural expiry date under Article 8 of the 2569 amendment.
Ongoing compliance obligations include:
Step 7: Plan for Renewal from Day One
Under Article 5 of the 2569 amendment, renewal is a substantive re-qualification, not an administrative extension. You must demonstrate current compliance with all four Article 8/1 criteria at renewal time. Under Article 6, any prior suspension for breach of Ministry of Public Health Notifications under Sections 44 and 45 of the Act results in mandatory denial of renewal.
Begin renewal preparation 6 months before expiry with a structured self-audit covering:
Thailand's 2026 framework demands continuous compliance, and the consequences of falling short have never been steeper. Sarun Sereethoranakul, whose company Iridescent Med operates under EU-GACP standards, explains what this means in practice: "From an operator's point of view, the key requirements are proper licensing, GACP cultivation, batch records, traceability, quality-control testing, secure storage, and complete documentation for every movement of product. Having a structured digital traceability and compliance system helps a lot during GACP audits." This operational perspective aligns with the formal requirements as follows:
Licensees must file Forms Phor.Tor.27, 28, and 29 monthly to DTAM, covering production, sales, inventory, and prescription verification. These must reconcile with Plookganja platform data; discrepancies are common audit triggers. Complete seed-to-sale traceability is mandatory: batch numbers, harvest dates, processing logs, testing results, and distribution records. Physical security requires restricted access, 24/7 surveillance, intrusion detection, visitor logs, and secure waste disposal. All records must be retained for the license period plus additional years. Maintain an audit-ready file with current licenses, staff training certificates, duty rosters, premises documentation, storage logs, odor system service records, GACP/GMP certifications, and monthly reports.
Labels must include product name, license number, THC/CBD content, expiration date, dosage instructions, warnings, and Ministry of Public Health approval marks. Claims cannot target minors, suggest recreational use, or promise unsubstantiated cures. Advertising is strictly prohibited to the general public under Sections 44 and 45 notifications; only direct professional medical channels are permitted. Every batch requires testing at Thai FDA-accredited labs for potency, microbes, heavy metals, pesticides, and mycotoxins. Costs run THB 3,000–10,000 per batch; failed batches must be quarantined or destroyed with documented evidence.
Despite the regulatory tightening of 2025–2026, Thailand retains genuine structural advantages for cannabis entrepreneurs and investors who understand the medical-only framework. The market has shifted from a free-for-all retail boom to a controlled, medically oriented system, but the underlying demand and export potential remain substantial.
The Thailand legal cannabis market was valued at USD 1.31 billion in 2024 and is projected to reach USD 7.10 billion by 2030, growing at a CAGR of 33.00%. Other projections are even more bullish, with forecasts suggesting Thailand could capture approximately 2.2% of the global cannabis market by 2030, making it the largest single market outside North America and Europe
The medical cannabis segment specifically was valued at USD 395.9 million in 2025 and is expected to reach USD 9,457.5 million by 2034, growing at a CAGR of 41.01%. Sarun Sereethoranakul of Iridescent Med sees this growth trajectory holding, but with a critical qualifier: "I believe both [expansion and tightening] will happen at the same time. Thailand will continue to support medical cannabis, Thai traditional medicine, research, and export opportunities, but the rules will become more structured and more strictly enforced. Companies with proper compliance, GACP, traceability, GMP thinking, and medical partnerships will have a future."
Thailand's domestic demand is driven by a large and growing patient population. Approximately 400 patients, including cancer patients, received cannabis oil at a flagship Bangkok clinic as early as January 2020, indicating early government commitment to medical access. The 2026 framework requires a PT 33 prescription for all cannabis flower purchases, which channels demand through licensed medical, pharmaceutical, and traditional medicine premises. While the closure of over 7,297 retail shops in 2025 contracted the storefront landscape, the remaining approximately 11,000 licensed establishments still represent a substantial distribution network for medical products.
The demand profile favors oils, tinctures, and non-smokable formats due to social stigma around smoking and regulatory restrictions on public consumption. Licensed physicians can prescribe cannabis for 15 specific medical conditions including cancer, chronic pain, epilepsy, and depression, subject to a 30-gram monthly limit per patient. As public awareness grows and more practitioners complete DTAM training, prescription volumes are expected to rise steadily.
Thailand's export pathway remains operational and strategically significant, though it requires navigating complex documentation and intermediary relationships. Out of more than 11,800 licensed cannabis-related operators, only 149 hold GACP certification, and an even smaller subset has verifiable international export histories. Thai-origin cannabis enjoys a documented presence in the Australian market, though buyers should verify actual shipment records rather than aggregate import statistics, which can be distorted by quota inflation.
Germany represents another target market, though Thai material often undergoes "GMP washing" through EU-GMP processing intermediaries in the Netherlands, Portugal, Czech Republic, Malta, or Germany itself before final market entry. This means Thai-origin cultivation is systematically undercounted in country-of-origin statistics, and operators describing themselves as "exporting to Germany" may be technically accurate while omitting the intermediary step. For buyers, the key diligence question is whether product moves under a Thai-origin EU-GMP manufacturing authorization or enters an EU-GMP processing step in a third country.
A common question among international investors is whether foreign capital can still participate in Thailand's cannabis industry post-2026. Sarun Sereethoranakul of Iridescent Med offers a clear-eyed assessment: Yes, foreign investors can still enter the market, but they need to structure the business carefully and work with properly licensed Thai entities. The market is no longer suitable for investors who only want to open simple recreational retail shops. The opportunity is still there, but it is now more suitable for long-term medical, pharmaceutical, export, technology, or compliance-focused investors."
The Foreign Business Act and Sanatorium Act limit foreign participation in medical operations, and Category 5 narcotics regulations require Thai-owned juristic persons for extract activities. Foreign investors typically require a Foreign Business License or Board of Investment promotion, with many structures capping foreign ownership at 49%.
The 2026 regulatory reset creates distinct investment opportunities for operators who can navigate the compliance landscape:
Is cannabis legal in Thailand in 2026?
Yes, but only for medical and health purposes. Recreational use is illegal. The April 30, 2026 Ministerial Regulation No. 2 B.E. 2569 reclassified cannabis flower as a controlled herb under the Herbal Product Act, requiring a PT 33 prescription for all purchases.
What is Ministerial Regulation No. 2 B.E. 2569?
It is the amendment to the Ministerial Regulation on the Permission for Study, Research, or Export of Controlled Herbs, or Sale, or Processing of Controlled Herbs for Commercial Purposes. Published in the Royal Gazette on April 30, 2026, it imposes four substantive approval criteria specifically for cannabis flower licenses: premises ownership, dedicated storage, qualifying applicant status, and trained staff on duty.
How much does a cannabis license cost in Thailand?
Government fees range from THB 5,000 for a dispensary to THB 50,000 for a cultivation license. A DTAM cannabis sales license costs THB 3,000 per 3 calendar years. However, total startup costs including premises, equipment, staffing, and compliance typically run THB 500,000 to 3,000,000.
Can foreigners own a cannabis business in Thailand?
Foreign ownership is restricted. The Foreign Business Act and Sanatorium Act limit foreign participation in medical and pharmacy operations. Foreign investors typically require a Foreign Business License or Board of Investment promotion, and many structures cap foreign ownership at 49%. Under the Category 5 narcotics regulation for extracts over 0.2% THC, applicants must be juristic persons that are not foreigners, government agencies, or the Thai Red Cross Society.
What license do I need to open a cannabis dispensary?
You need a controlled-herbs sale license under Section 46 of the Protection and Promotion of Thai Traditional Medicine Knowledge Act B.E. 2542, plus an underlying health-sector credential such as a hospital license, herbal product license, pharmaceutical license, Category 5 narcotics license, or folk healer certification. The freestanding retail dispensary model is no longer viable.
How long does the license application take?
Applications filed directly with DTAM in Bangkok take 2 to 3 months. Provincial health office routes require 4 to 5 months. Incomplete paperwork or failed premises inspections add weeks.
What is GACP certification?
Good Agricultural and Collection Practice certification from the Thai FDA and DTAM. It is mandatory for cultivators and covers standard operating procedures for cultivation, harvesting, processing, and quality control. Only 149 of over 11,800 licensed operators currently hold GACP certification.
What is the Plookganja platform?
The government's digital registration and tracking system for cannabis cultivation, inventory, and sales. All licensees must integrate with Plookganja for real-time reporting.
Can I import cannabis into Thailand?
Importing cannabis or cannabis products for personal use is strictly prohibited. For research or medical purposes, specific authorization from the Thai FDA and Ministry of Public Health is required. Importing cannabis seeds also requires FDA authorization under plant quarantine regulations.
Can I export cannabis from Thailand?
Yes, but with strict conditions. Cannabis flower exports require proof of the destination market's import permit and buyer authorization. Extracts over 0.2% THC require specific permission for each transaction, and exporters must be Thai-owned juristic persons, government agencies, or the Thai Red Cross Society.
What happens if my license is suspended?
Under Article 6 of Ministerial Regulation No. 2 B.E. 2569, any licensee previously suspended for non-compliance with Ministry of Public Health Notifications under Sections 44 and 45 of the Act is barred from renewal entirely. This is mandatory and irreversible.
What are the penalties for recreational use?
Public consumption without a valid prescription carries a fine up to THB 25,000 and imprisonment up to 3 months. Possession or purchase without a prescription carries identical penalties. Operating an unlicensed dispensary results in closure, fines, and potential criminal charges.
What medical conditions qualify for cannabis prescription?
Licensed physicians can prescribe cannabis for 15 specific conditions including Alzheimer's, chronic pain, epilepsy, depression, and cancer, subject to a 30-gram monthly limit per patient.
Do I need a pharmacist on staff?
Under Article 8/1(4) of the 2569 regulation, at least one staff member who has completed DTAM training must be present throughout operating hours. While not always a licensed pharmacist, the qualifying applicant status often requires pharmaceutical or medical credentials.
What is the THC limit for hemp?
Hemp is defined as cannabis containing less than 0.2% THC by dry weight. Extracts exceeding this threshold remain classified as Category 5 narcotics regardless of source plant.
